FORM PTO-1449 (modified)

OIPE JC174 OCT 13 2004 PATENT TRADEMARK OFFICE

Atty. Ref. No.	Client Ref
037003-0275681	1995-30-0233CP2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: ANDERSON et al.

Appln. No.: 09/576,424

Filing Date: May 22, 2000

Dat : October 13, 2004 Page 1 of 4 Examiner: Gambel, P. Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)
PG	AR	4,816,397	03/1989	Boss
	BR	4,816,567	03/1989	Cabilly
	CR	5,116,964	05/1992	Capon
	DR	5,304,635	04/1994	Imam
	ER	5,434,131	07/1995	Linsley
	FR	5,885,579	03/1999	Linsley
	GR	6,162,432	12/2000	Wallner

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract		Translation Readily Availabl	
							Enclosed	No	Enclose	No
PG	HR	0 171 496 B1	05/1993	EP	Taniguchi, et al.					
	IR	0 173 494 A2	03/1986	EP	Morrison, et al.					
	JR	0 239 400 B1	08/1994	EP	Winter, et al.					
	KR	0 194 276 A1	03/1986	EP	Neuberger, et al.					
	LR	0 451 216 B1	10/1991	EP	Queen					
	MR	0 555 880 A2, A3	08/1993	EP	Aruffo, et al.					
	NR	0 682 040 A1	11/1995	EP	Queen					
	OR	2 177 096 A	03/1986	GB	Neuberger, et al.					
	PR	WO 92/06193	04/1992	WO	Gorman, et al.					
	QR	WO 93/09812	05/1993	WO	Lederman, et al.					
	RR	WO 94/28912	12/1994	WO	Thompson, et al.					
	SR	WO 95/06481	03/1995	WO	Noelle, et al.					
	TR	WO 95/06666	03/1995	WO	Noelle, et al.					
	UR	WO 98/19706	05/1998	WO	Anderson, et al.					

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	VR	Alegre M., et al, "Effect of single amino acid mutation on the activating and immunosuppressive properties of a "Humanized" OKT3 monoclonal antibody," J. Immunol., 1992, 148:3461-3468.
	WR	Armitage R.J., et al., "Molecular and biologial characterization of a murine ligand for CD40," Nature, 1992, 357:80-82.
	XR	Azuma M., et al., "CD28 Interaction with B7 Costimulates Primary Allogeneic Proliferative Responses and Cytotoxicity Mediated by Small Resting T Lymphocytes," J. Exp. Med., 1992, 175:353-360.
	YR	Azuma M., et al., "Functional Expression of B7/BB1 on Activated T Lymphocytes," J. Exp. Med., 1993, 177:845-850.
	ZR	Azuma M.D., et al., "B70 Antigen is a Second Ligand for CTLA-4 and CD28," Nature, 1993, 366:76-79.
	AAR	Ben-Nun A., et al., "The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis," Eur J. Immunol., 1981, 11:195-199.
	BBR	Blazar B.R., t al., "Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct ffects on CD4+ and CD8+ T cells," J Immunol., 1996, 157:3250-3259.
	CCR	Boussiotis V.A., et al., "Activat d human B lymph cytes expr ss thre CTLA-4 counter-receptors that co-stimulat T-Cell activation," Proc. Natl. Acad. Sci., USA, 1993, 90:11059-11063.

PHILIP GAMBEL 1/7/05

	DDR	Capon D.J., et al., "Designing CD4 immunoadhesins for AIDS th rapy," Nature, 1989, 337, 525-531.
	EER	Cohen J., "New protein st als the show as 'costimulator' of T cells," Sci nce, 1993, 262:844-845.
	FFR	Cohen J., "M unting a targeted strik on unwanted immun responses," (n ws; comm nt), Science, 1992, 257:751.
	GGR	Dautigny A., et al., "Molecular cloning and nucle tide sequence of a cDNA clone coding for rat brain myelin proteolipid," FEBS Lett., 1985, 188(1):33-36.
	HHR	D Boer M., et al., "Functi nal Characterization of a Nov l Anti-B7 Monoclonal Antib dy," Eur. Journal of Immunology, 1992, 22:3071-3075.
	IIR	Delabie J., et al., "Th B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's dis ase and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines," Blood, 1993, 82:2845-52.
	JJR	Dermer G.B., et al., "Another Anniversary for the war on cancer," Biotechnology, 1994, 12:320.
	KKR	Dillman R.O., et al., "Antibodies as cytotoxic therapy," 1994, J Clin Oncol., 12:1497-1515.
	LLR	Durie F.H., et al., "The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease," Research in Immunology, 1994, 145(3), 200-205 & 244-249.
	MMR	Durie F.H., et al., "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40," Science, 1993, 261:1328-1330.
	NNR	Engel et al, "The B7-2 (B70) costimulatory molecule expressed by monocytes and activted B lymphocytes is the CD86 differentiation antigen," Blood, 1994, 84, 1402-1407.
	OOR	Falini B., et al., "Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin," The Lancet, 1992, 339:1195-1196.
	PPR	Freeman G.J., et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mic ," Science, 1993, 262:907-909.
	QQR	Freeman G.J., et al., "CTLA-4 and CD28 MRNA are Coexpressed in Most T Cells After Activation," The Journal of Immunology, 1992, 149:3795-3801
	RRR	Freeman G.J., et al., "Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation," Science, 1993, 262:909-911.
	SSR	Geenen V. and G. Kroemer, "Multiple Ways to Cellular Immune Tolerance," Immunology Today, 1993, 14:573.
	TTR	Gerritse K., et al., "CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis," Proc. Natl. Acad. Sci. USA, 1996, 93:2499-2504.
	UUR	Gimmi C.D., et al., "Human T-Cell Clonal Anergy is Induced by Antigen Presentation in the Abs nce f B7 Costimulation," Proc. Natl. Acad. Sci., 1993, 90:6586-6590.
	VVR	Gottlieb A., et al., "Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis," J Invest Dermatol., 2000, 114:840, Abstract No. 546.
	WWR	Gottlieb A., et al., "Clinical and histologic response to single-dose treatment of moderate to sev r psoriasis with an anti-CD80 monoclonal antibody," J Am Acad Dermatol., 2002, 47:692-700.
	XXR	Gribben J.G., et al., "CTLA-4 mediates antigen specific apoptosis of human T cells." Proc. Natl. Acad. Sci. USA, 1995, 92:811-815.
	YYR	Grumet F.C., et al., "Soluble form of an HLA-B7 Class I Antigen Specifically Suppresses Humoral Alloimmunization." Human Immunology, 1995, 40:228-234.
	ZZR	Guinan E.C., et al., "Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity," Blood, 1994, 84:3261-3282.
	AAAR	Hafler D.A., et al., "The potential of restricted T cell recognition of myelin basis protein epitopes in the therapy of multiple sclerosis," Ann. NY Acad. Sci., 1991, 636:251-265.
	BBBR	Harding F.A., et al., "CD28 Mediated Signalling Co-stimulates Murine T Cells and Prevents Induction of Anergy in T Cell Clones." Nature, 1992, 356:607-609.
	CCCR	Hariharan K., et al., "Therapeutic activity of IDEC-114 (anti-CD80) and rituximab (Rituxan®) in B-cell lymphoma," Blood, 2001, 98(11 part 1):608a, Abstract No. 2549.
	DDDR	Hart D.N.J., et al., "B7/BB-1 is a Leucocyte Differentiation Antigen on Human Dendritic Cells Induced by Activation." Immunology, 1993, 79:616-620
	EEER	Hathcock K.S., et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science, 1993, 262:905-907.
	FFFR	Hollenbaugh D., et al., "The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity," The EMBO J., 1992, 11(12):4313-4321.
	GGGR	Ionescu-Tirgoviste, et al, "Correlations between insulin antibodies and the HLA system in a group of Typ I diabetic patients in Bucharest," Med. Int rre, 1986, 24(1), 11-17.

PHILIP GAMBEL 1/7/05

	HHHR	Janeway C.A., Jr. and K. Bottomly, "Signals and Signs for Lymphocyt R sponses," Cell, 1994, 76.275-285.
	IIIR	Jenkins M.K., "The Role of Cell Division in the Induction of Clonal Anergy." Immunology Today, 1992, 13:69.
	JJJR	June C.H., et al., "The B7 and CD28 receptor families," Immunol Today, 1994, 15:321-331.
	KKKR	Kahan B.D., Immunosuppressive therapy, Curr Opin Immunol., 1992, 4:553-560.
	LLLR	Karpus,W.J., et al., "CD4+ suppressor cells differentially aff ct the production of IFN-γ by effector cells of experimental autoimmune encephalomyelitis," J. Immunol., 1989, 143:3492-3497.
	MMMR	Krumm l M., et al., "CD28 and CTLA-4 hav opposing effects on the response of T cells to stimulation," J. Exp. Med. 1995, 182:459-466.
	NNNR	Laman J., et al., "The role of gp39 (CD40 ligand) in EAE and MS," Journal of Neuroimmunology, 1994, 54(1-2):175, Abstract No. P01.06
	OOOR	LaSalle J.M., et al., "Early signaling defects in human T cells anergized by T cell presentation of autoantigen," J. Exp. Med., 1992, 176:177-186.
	PPPR	Lederman S., et al., "Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help)," J. Exp. Med., 1992, 175:1091-1101.
	QQQR	Lenschow D.J., et al., "Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA-4Ig," Science, 1992, 257:789-795.
	RRRR	Lenschow D.J., et al., "Expression and Functional Significance of an Additional Ligand for CTLA-4," Proc. Natl. Acad. Sci., USA,,1993, 90:11054-11058.
	SSSR	Lider O., et al., "Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein," J. Immunol., 1989, 142:748-752.
	TTTR	Lin H., et al., "Long-term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA-4-Ig Plus Donor Specific Transfusion," J. Exp. Med., 1993, 178:1801.
	UUUR	Linsley, P.S. et al., "The role of the CD28 receptor during T cell responses to antigen," Annu R v Immunol., 1993, 11:191-212.
	VVVR	Linsley, P.S., et al., "CTLA-4 is a Second Receptor for the B Cell Activation Antigen B7," J. Exp. Med., 1991, 174:561.
	WWWR	Linsley P.S., et. al., "T-Cell Antigen CD28 Mediates Adhesion with B Cells by Interacting with Activation Antigen B7/BB-1." Proc. Natl. Acad. Sci., 1990, 87:5031-5035.
	XXXR	Linsley, et al, "CD28 Engagement by B7/BB-1 Induces Transient Down-Regulation of CD28 Synthesis and Prolonged Unresponsiveness to CD28 Signaling," The Journal of Immunology, 1993, 150:3161-3169.
	YYYR	Linsley, et al., "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferati n and interleukin 2 mRNA accumulation," J. Exp. Med., 1991, 173:721-730.
	ZZZR	Linsley P.S., et. al., "Coexpression and Functional Cooperation of CTLA-4 and CD28 on Activated T Lymphocytes." J. Exp. Med., 1992, 176:1595-1604.
	AAAAR	Liu, et al., "Blockade of CD28/CTLA-4-B7 co-stimulatory pathway in colitic SCID mice," Gastroent rology, April 2000, Part 1 of 2, 118(4 Suppl 2):AGA-A575, Abstract No. 3000.
	BBBBR	McCafferty J., et al., "Phage antibodies: filamentous phage displaying antibody variable domains," Nature, 1990, 348:552-554.
	CCCCR	Miller A., et al., "Antigen-driven bystander suppression after oral administration of antigens," J. Exp. Med., 1991, 174:791-798.
	DDDDR	Mokhtarion F., et al., "Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice," Nature, 1984, 309:356-358.
	EEEER	Morrison S., et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad, Sci. U.S.A., 1984, 81:6851-6855.
	FFFFR	Morton P.A., et al., "Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2)," J. Immunol., 1996,156:1047-1054.
	GGGGR	Munro J.M., et al., "In vivo expression of the B7 costimulatory molecule by subsets of antigen-pr senting cells and the malignant cells of Hodgkin's disease," Blood, 1994, 83:793-798.
	HHHHR	Nestle F.O., et al, "Characterization of dermal dendritic cells in psoriasis," J. Clin. Invest., 1994, 94: 202-209.
	IIIIR	Nickoloff B.J. et al., "T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand f r CD28," Blood, 1994, 83(9):2580-2586.
	JJJJR	Noelle R.J., et al., "A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal f r cognate activation of B cells," Proc. Natl. Acad. Sci. USA, 1992, 89:6550-6554.
	KKKKR	Olsson L., et al., "Human-human m noclonal antibody-producing hybridomas: technical aspects," Meth, Enzym l., 1983, 92:3-17.

	LLLLR	Perrin P.J. et al., "Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on exp rimental allergic encephalomyelitis," J.Neuroimmunol., 1996, 65:31-39.
	MMMMR	Pesoa S.A., et al., "Regulation of experimental allergic encephalomyelitis. Part 5. Rol of the recipient in suppress r cell induction," J. N uroimmunol, 1984, 7:131-135.
	NNNNR	Pettinelli C.B., et al., "Adoptive transfer of experimental all rgic encephalomyelitis in SJL/J mice after *in vitro* activation of lymph node cells by myelin basic protein: requirement for Lyt 1^+ 2^- T lymphocytes," J. Immunol., 1981, 127:1420-1423.
	OOOOR	Schwartz R.H., "Co-stimulation of T lymphocytes: The role f CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," Cell, 1992, 71:1065-1068.
	PPPPR	Schwartz R.H., "A cell culture model for T lymphocyte clonal anergy," Science, 1990, 248:1349-1356.
	QQQQR	Selvakumar,A., et al., "Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7," Immunogenetics, 1992, 36:175-181
	RRRRR	Sobel R.A., et al., "Acute experimental allergic encephalomyelitis in SJL/J mice induced by a synth tic peptide of myelin proteolipid protein," J. Neuropathol. Exp. Neurol., 1990, 49(5):468-479.
	SSSSR	Stamenkovic I., et al., "A B-lymphocyte activation molecule related to the nerve growth factor r ceptor and induced by cytokines in carcinomas," The EMBO J., 1989, 8(5),1403-1410.
	TTTTR	Suvas S., et al., "Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma," J Biol Chem., 2002, 277(10):7766-7775.
	UUUUR	Takeda S., et al., "Construction of chimaeric processed immunoglobulin genes containing mous variable and human constant region sequences," Nature, 1985, 314(4):452-454.
	VVVVR	Tan P., et al., "Induction of Alloantigen-specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with Its Natural Ligand B7/BB1," J. Exp. Med., 1993, 177:165-173.
	WWWWR	Teng N. H. et al., "Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production," Proc. Natl. Acad. Sci. U.S.A., 1983, 80:7308-7312.
	XXXXR	Tivol E.A., et al., "Loss of CTLA-4 leads to massive lymphoproli-feration and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4," Immunity, 1995, 3:541-547.
	YYYYR	Turka L.A., et al., "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo," Proc. Natl. Acad. Sci., USA, 1992, 89:11102-11105.
	ZZZZR	Toubert A., et al., "Epitope mapping of an HLA-B27 monoclonal antibody that also reacts with a 35-kD bacterial out-membrane protein," Clin. Exp. Immunol., 1990, 82(1), 16-20.
	AAAAAR	Toubert A., et al., "Epitope mapping of HLA-B27 and HLA-B7 antigens by using intradomain recombinants," J. Immunol., 1988, 141(7), 2503-9.
	BBBBBR	Tuohy V.K., et al., "Identification of an encephalitogenic determinant of myelin proteolipid prot in for SJL mice," J. Immunol., 1989, 142:1523-1527.
	CCCCCR	Valle et al., "mAb 104, a new monoclonal antibody, recognizes the B7 antigen that is expressed on activated B cells and HTLV-1-transformed T cells," Immunol., 1990, 69(4), 531-535.
	DDDDDR	Vandenberghe P., et al.. "Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells," J. Exp. Med., 1992, 175:951-960.
	EEEEER	van der Merwe, et al., "CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics," J. Exp. Med., 1997,185: 393-403.
	FFFFFR	Van der Veen R. C., et al., "The adoptive transfer of chronic relapsing experimental allergic encephalomyelitis with lymph node cells sensitized to myelin proteolipid protein," J. Neuroimmunol., 1989, 21:183-191.
	GGGGGR	Ward E.S., et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," Nature, 1989, 341:544-546.
	HHHHHR	Ward P.A., et al., "Blocking of adhesion molecules in vivo as anti-inflammatory therapy," Ther Immunol., 1994, 1:165-171.
	IIIIIR	Weyl D., et al., "Epitope mapping of human monoclonal antibodies to HLA-B27 by using natural and mutated antigenic variants," Hum. Immunol., 1991, 31(4), 271-276.
	JJJJJR	Yi-qun Z. et al., Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens, Int Immunol., 1996, 8:37-44.
	KKKKKR	Zavazava N., et al, "Inhibition of anti-HLA-B7 alloreactive CTL by affinity-purified soluble HLA," Transplantation, 1991, 51(4), 838-42.

Examin r PHILLIP GAMBEL 1/7/05	Dat Considered:

*EXAMINER: Initial if citation considered, whether or not citati n is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with n xt communication t Applicant.